Cedars-Sinai Cancer | Strategic Alliance Partners

April 26, 2023

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

April 24, 2023

Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men.

April 21, 2023

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

April 19, 2023

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

April 19, 2023

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

April 18, 2023

Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.

April 12, 2023

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

April 12, 2023

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

April 05, 2023

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

April 05, 2023

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

March 29, 2023

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

March 29, 2023

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

March 22, 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

March 22, 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

March 03, 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

March 03, 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

February 15, 2023

Cedars-Sinai investigators verify that rates are trending up for both sexes; younger women and Black women see steepest increase.

December 19, 2022

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

November 03, 2022

Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.

October 31, 2022

Cedars-Sinai cancer researchers identify new biomarkers linked with patient response to immunotherapy for many types of cancers.